Novel therapies for Helicobacter pylori infection |
| |
| Authors: | OPEKUN,EL-ZAIMAITY,OSATO,GILGER,MALATY,TERRY,HEADON,& GRAHAM |
| |
| Affiliation: | Department of Medicine, Baylor College of Medicine, Texas Children's Hospital, Veterans Affairs Medical Center, USA,;Department of Paediatrics, Baylor College of Medicine, Texas Children's Hospital, Veterans Affairs Medical Center, USA; Department of Pathology, Baylor College of Medicine, Texas Children's Hospital, Veterans Affairs Medical Center, USA,;Agennix, Houston, Texas, USA,;Department of Molecular Virology, Baylor College of Medicine, Texas Children's Hospital, Veterans Affairs Medical Center, USA |
| |
| Abstract: | Background: Increasing antibiotic resistance has begun to impair our ability to cure Helicobacter pylori infection. Aim: To evaluate orally administered novel therapies for the treatment of H. pylori infection. Methods: Healthy H. pylori infected volunteers received: (a) hyperimmune bovine colostral immune globulins, (b) an oligosaccharide containing an H. pylori adhesion target, Neu5Aca2-3Galb1–4Glc-(3′-sialyllactose), or (c) recombinant human lactoferrin. Outcome was assessed by urea breath test or histological assessment of the number of H. pylori present. Results: None of the novel therapies appeared effective and no adverse events occurred. Conclusion: Although in vitro data appeared promising, in vivo results were disappointing. Higher doses, longer duration of therapy, adjunctive acid suppression, or a combination could possibly yield better results. |
| |
| Keywords: | |
|
|
